ViaCyte, Inc. Company Profile

09:03 EDT 20th September 2017 | BioPortfolio

News Articles [13 Associated News Articles listed on BioPortfolio]

ViaCyte Raises $10M, Moves to Human Trial with New Diabetes Product

San Diego-based ViaCyte said it is ready to move into human testing with a new product intended for patients with Type 1 diabetes who are at high risk for acute, life-threatening complications from se...

ViaCyte to study PEC-Direct in international clinical trial for type 1 diabetes

US-based regenerative medicine firm ViaCyte has obtained approval for its investigational new drug (IND) application from both the US Food and Drug Administration and Health Canada to initiate a clini...

ViaCyte to Present at Upcoming Scientific Meetings on Diabetes Research

SAN DIEGO, Sept. 7, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held, leading regenerative medicine company, today announced upcoming scientific presentations.  ViaCyte is developing nov...

ViaCyte raises $10mm

Regenerative medicine firm ViaCyte Inc. raised $10mm in a late-stage financing from Asset Management Partners, WL Gore & Associates, JDRF, and undisclosed current investors. The company will use the f...

Viacyte Aims To Improve On The Artificial Pancreas

ViaCyte Presents at the ISSCR 2017 Annual Meeting in Boston

SAN DIEGO, June 15, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced a presentation at the International Society for Stem Cell Research (ISSCR) ...

ViaCyte Announces $10 Million in Financing

SAN DIEGO, May 22, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held leading regenerative medicine company, announced today $10 million in financing to support operations.  Participants i...

JDRF and ViaCyte Announce Support for Development of PEC-Direct Cell Replacement Therapy for Type 1 Diabetes

NEW YORK and SAN DIEGO, May 22, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held leading regenerative medicine company, and JDRF, the leading global organization funding type 1 diabetes resea...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Safety and Efficacy of Freezing and Thawing of Human Eggs in Assisted Reproductive Technology

The purpose of this study is to determine the effectiveness of the ViaCyte media for freezing and thawing human eggs for future use in assisted reproductive technology.

More Information about "ViaCyte, Inc." on BioPortfolio

We have published hundreds of ViaCyte, Inc. news stories on BioPortfolio along with dozens of ViaCyte, Inc. Clinical Trials and PubMed Articles about ViaCyte, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ViaCyte, Inc. Companies in our database. You can also find out about relevant ViaCyte, Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record